EDUCATION

Undergraduate Degree

  • Princeton University , 1984 , Princeton , NJ

Medical School

  • University of Wisconsin , 1988 , Madison , WI

Internship

  • Beth Israel Deaconess Medical Center , 1995 , Boston , MA

Residency

  • Beth Israel Deaconess Medical Center , 2000 , Boston , MA

Fellowship

Pediatric Radiology
  • Boston Children's Hospital , 2001 , Boston , MA

CERTIFICATIONS

  • American Board of Radiology, Diagnostic Radiology
  • American Board of Radiology, Nuclear Radiology
  • American Board of Radiology, Pediatric Radiology

PUBLICATIONS

Publications powered by Harvard Catalyst Profiles

  1. Response to Febo-Rodriguez et al. Am J Gastroenterol. 2021 Jul 01; 116(7):1553. View abstract
  2. Activity of Crizotinib in Patients with ALK-Aberrant Relapsed/Refractory Neuroblastoma: A Children's Oncology Group Study (ADVL0912). Clin Cancer Res. 2021 Jul 01; 27(13):3543-3548. View abstract
  3. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 11; 115(11):1830-1839. View abstract
  4. Pediatric Solid Gastric Emptying Scintigraphy: Normative Value Guidelines and Nonstandard Meal Alternatives. Am J Gastroenterol. 2020 Aug 19. View abstract
  5. Expert consensus statements for Waldeyer's ring involvement in pediatric Hodgkin lymphoma: The staging, evaluation, and response criteria harmonization (SEARCH) for childhood, adolescent, and young adult Hodgkin lymphoma (CAYAHL) group. Pediatr Blood Cancer. 2020 09; 67(9):e28361. View abstract
  6. Neck CT angiography examinations for pediatric oropharyngeal trauma: diagnostic yield and proposal of a new targeted technique. Pediatr Radiol. 2020 10; 50(11):1602-1609. View abstract
  7. Prospective Evaluation of Radiation Dose Escalation in Patients With High-Risk Neuroblastoma and Gross Residual Disease After Surgery: A Report From the Children's Oncology Group ANBL0532 Study. J Clin Oncol. 2020 08 20; 38(24):2741-2752. View abstract
  8. Liver involvement in pediatric Hodgkin lymphoma: A systematic review by an international collaboration on Staging Evaluation and Response Criteria Harmonization (SEARCH) for Children, Adolescent, and Young Adult Hodgkin Lymphoma (CAYAHL). Pediatr Blood Cancer. 2020 08; 67(8):e28365. View abstract
  9. Normative database of spatiotemporal gait parameters using inertial sensors in typically developing children and young adults. Gait Posture. 2020 07; 80:206-213. View abstract
  10. Definition of cortical bone involvement in the staging of newly diagnosed pediatric Hodgkin lymphoma: A report from the International Working Group on Staging Evaluation and Response Criteria Harmonization (SEARCH). Pediatr Blood Cancer. 2020 04; 67(4):e28142. View abstract
  11. Phase I Clinical Trial of the Wee1 Inhibitor Adavosertib (AZD1775) with Irinotecan in Children with Relapsed Solid Tumors: A COG Phase I Consortium Report (ADVL1312). Clin Cancer Res. 2020 03 15; 26(6):1213-1219. View abstract
  12. Functional and anatomical imaging in pediatric oncology: which is best for which tumors. Pediatr Radiol. 2019 10; 49(11):1534-1544. View abstract
  13. Surveillance imaging in pediatric lymphoma. Pediatr Radiol. 2019 10; 49(11):1565-1573. View abstract
  14. Effect of Tandem Autologous Stem Cell Transplant vs Single Transplant on Event-Free Survival in Patients With High-Risk Neuroblastoma: A Randomized Clinical Trial. JAMA. 2019 08 27; 322(8):746-755. View abstract
  15. Impact of a Two-Filter Cerebral Embolic Protection Device on the Complexity and Risk of Transcatheter Aortic Valve Replacement. Thorac Cardiovasc Surg. 2020 10; 68(7):616-622. View abstract
  16. Multicenter pre-operative assessment of pediatric ovarian malignancy. J Pediatr Surg. 2019 Sep; 54(9):1921-1925. View abstract
  17. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clin Cancer Res. 2019 06 01; 25(11):3229-3238. View abstract
  18. Staging and following common pediatric malignancies: MRI versus CT versus functional imaging. Pediatr Radiol. 2018 08; 48(9):1324-1336. View abstract
  19. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children's Oncology Group. Cancer. 2018 08 01; 124(15):3210-3219. View abstract
  20. A phase 1 study of cabozantinib in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: Trial ADVL1211, a report from the Children's Oncology Group. Pediatr Blood Cancer. 2018 08; 65(8):e27077. View abstract
  21. Correction to: Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol. 2018 03; 48(3):454. View abstract
  22. Mid-Term Results After Sternal Reconstruction Using Titanium Plates: Is It Worth It to Plate? Ann Thorac Surg. 2018 06; 105(6):1640-1647. View abstract
  23. Imaging Optimization in Children. J Am Coll Radiol. 2018 03; 15(3 Pt A):440-443. View abstract
  24. Ionizing radiation from computed tomography versus anesthesia for magnetic resonance imaging in infants and children: patient safety considerations. Pediatr Radiol. 2018 01; 48(1):21-30. View abstract
  25. How we read pediatric PET/CT: indications and strategies for image acquisition, interpretation and reporting. Cancer Imaging. 2017 Nov 07; 17(1):28. View abstract
  26. Liposuction for Swelling in Patients with Lymphedema. N Engl J Med. 2017 11 02; 377(18):1788-1789. View abstract
  27. Screening with whole-body magnetic resonance imaging in pediatric subjects with Li-Fraumeni syndrome: A single institution pilot study. Pediatr Blood Cancer. 2018 Feb; 65(2). View abstract
  28. Role of imaging in the diagnosis of parotid infantile hemangiomas. Int J Pediatr Otorhinolaryngol. 2017 Nov; 102:61-66. View abstract
  29. Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study. J Clin Oncol. 2017 Oct 01; 35(28):3215-3221. View abstract
  30. Operational and Dosimetric Aspects of Pediatric PET/CT. J Nucl Med. 2017 09; 58(9):1360-1366. View abstract
  31. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 1. Clin Cancer Res. 2017 Jun 15; 23(12):e46-e53. View abstract
  32. Cancer and Central Nervous System Tumor Surveillance in Pediatric Neurofibromatosis 2 and Related Disorders. Clin Cancer Res. 2017 Jun 15; 23(12):e54-e61. View abstract
  33. Von Hippel-Lindau and Hereditary Pheochromocytoma/Paraganglioma Syndromes: Clinical Features, Genetics, and Surveillance Recommendations in Childhood. Clin Cancer Res. 2017 Jun 15; 23(12):e68-e75. View abstract
  34. Pediatric Cancer Predisposition Imaging: Focus on Whole-Body MRI. Clin Cancer Res. 2017 Jun 01; 23(11):e6-e13. View abstract
  35. Evaluation of the utility of 99m Tc-MDP bone scintigraphy versus MIBG scintigraphy and cross-sectional imaging for staging patients with neuroblastoma. Pediatr Blood Cancer. 2017 Nov; 64(11). View abstract
  36. Hepatocellular Carcinoma in Fanconi-Bickel Syndrome. Pediatr Dev Pathol. 2018 Jan-Feb; 21(1):84-90. View abstract
  37. Staging Evaluation and Response Criteria Harmonization (SEARCH) for Childhood, Adolescent and Young Adult Hodgkin Lymphoma (CAYAHL): Methodology statement. Pediatr Blood Cancer. 2017 Jul; 64(7). View abstract
  38. Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group. Pediatr Blood Cancer. 2017 04; 64(4). View abstract
  39. Features and Outcome of Autonomous Thyroid Nodules in Children: 31 Consecutive Patients Seen at a Single Center. J Clin Endocrinol Metab. 2016 10; 101(10):3856-3862. View abstract
  40. Post-transplant lymphoproliferative disorder of the pediatric airway: Presentation and management. Int J Pediatr Otorhinolaryngol. 2016 Jul; 86:218-23. View abstract
  41. Poor adherence to staging guidelines for children with malignant ovarian tumors. J Pediatr Surg. 2016 Sep; 51(9):1513-7. View abstract
  42. The ionic charge of copper-64 complexes conjugated to an engineered antibody affects biodistribution. Bioconjug Chem. 2015 Apr 15; 26(4):707-17. View abstract
  43. Growth plate abnormalities in pediatric cancer patients undergoing phase 1 anti-angiogenic therapy: a report from the Children's Oncology Group Phase I Consortium. Pediatr Blood Cancer. 2015 Jan; 62(1):45-51. View abstract
  44. Surveillance imaging in pediatric Hodgkin Lymphoma. Curr Hematol Malig Rep. 2013 Sep; 8(3):218-25. View abstract
  45. Phase 2 trial of cixutumumab in children, adolescents, and young adults with refractory solid tumors: a report from the Children's Oncology Group. Pediatr Blood Cancer. 2014 Mar; 61(3):452-6. View abstract
  46. Phase I pharmacokinetic and pharmacodynamic study of pazopanib in children with soft tissue sarcoma and other refractory solid tumors: a children's oncology group phase I consortium report. J Clin Oncol. 2013 Aug 20; 31(24):3034-43. View abstract
  47. The radiographic appearance of split Blake drains: what you see is not necessarily what you get. Pediatr Radiol. 2013 Dec; 43(12):1573-6. View abstract
  48. A comparison of 2 intravenous lipid emulsions: interim analysis of a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014 Aug; 38(6):693-701. View abstract
  49. Resolving bony abnormality evolves to diffuse large B-cell lymphoma. Pediatr Blood Cancer. 2013 Oct; 60(10):E113-5. View abstract
  50. A low-glycemic-load versus low-fat diet in the treatment of fatty liver in obese children. Child Obes. 2013 Jun; 9(3):252-60. View abstract
  51. Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study. Lancet Oncol. 2013 May; 14(6):472-80. View abstract
  52. Reliable estimation of incoherent motion parametric maps from diffusion-weighted MRI using fusion bootstrap moves. Med Image Anal. 2013 Apr; 17(3):325-36. View abstract
  53. In vivo assessment of optimal b-value range for perfusion-insensitive apparent diffusion coefficient imaging. Med Phys. 2012 Aug; 39(8):4832-9. View abstract
  54. Surveillance computed tomography imaging and detection of relapse in intermediate- and advanced-stage pediatric Hodgkin's lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jul 20; 30(21):2635-40. View abstract
  55. Reliable assessment of perfusivity and diffusivity from diffusion imaging of the body. Med Image Comput Comput Assist Interv. 2012; 15(Pt 1):1-9. View abstract
  56. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012 Jan 20; 30(3):256-62. View abstract
  57. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study. Neuro Oncol. 2011 Aug; 13(8):910-5. View abstract
  58. Leukemia and lymphoma. Radiol Clin North Am. 2011 Jul; 49(4):767-97, vii. View abstract
  59. Adrenal cortical tumors in children: factors associated with poor outcome. J Pediatr Surg. 2011 Jun; 46(6):1201-7. View abstract
  60. Pediatric oncology and the future of oncological imaging. Pediatr Radiol. 2011 May; 41 Suppl 1:S172-85. View abstract
  61. Quantitative body DW-MRI biomarkers uncertainty estimation using unscented wild-bootstrap. Med Image Comput Comput Assist Interv. 2011; 14(Pt 2):74-81. View abstract
  62. Phase II study of irinotecan and temozolomide in children with relapsed or refractory neuroblastoma: a Children's Oncology Group study. J Clin Oncol. 2011 Jan 10; 29(2):208-13. View abstract
  63. Imaging cancer using PET--the effect of the bifunctional chelator on the biodistribution of a (64)Cu-labeled antibody. Nucl Med Biol. 2011 Jan; 38(1):29-38. View abstract
  64. Antitumor activity of hu14.18-IL2 in patients with relapsed/refractory neuroblastoma: a Children's Oncology Group (COG) phase II study. J Clin Oncol. 2010 Nov 20; 28(33):4969-75. View abstract
  65. Synovial sarcoma in children: imaging features and common benign mimics. AJR Am J Roentgenol. 2010 Oct; 195(4):1026-32. View abstract
  66. Diagnostic errors in pediatric radiology. Pediatr Radiol. 2011 Mar; 41(3):327-34. View abstract
  67. Primary lung tumors in children and adolescents: a 90-year experience. J Pediatr Surg. 2010 Jun; 45(6):1090-5. View abstract
  68. Effects of neoadjuvant chemotherapy on hepatoblastoma: a morphologic and immunohistochemical study. Am J Surg Pathol. 2010 Mar; 34(3):287-99. View abstract
  69. In utero diagnosis of congenital pyloric atresia in a single twin using MRI and ultrasound. J Pediatr Surg. 2009 Nov; 44(11):e21-4. View abstract
  70. The ALARA concept in pediatric oncology. Pediatr Radiol. 2009 Nov; 39(11):1142-6. View abstract
  71. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer. 2009 Aug; 53(2):162-7. View abstract
  72. Irinotecan plus temozolomide in children with recurrent or refractory neuroblastoma: A phase II Children's Oncology Group study. J Clin Oncol. 2009 May 20; 27(15_suppl):10011. View abstract
  73. Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study. J Clin Oncol. 2008 Oct 20; 26(30):4921-7. View abstract
  74. A paradoxical signal intensity increase in fatty livers using opposed-phase gradient echo imaging with fat-suppression pulses. Pediatr Radiol. 2008 Oct; 38(10):1099-104. View abstract
  75. Prenatal diagnosis and subsequent treatment of an intermediate-risk paraspinal neuroblastoma: case report and review of the literature. Fetal Diagn Ther. 2008; 24(2):119-25. View abstract
  76. Positron emission tomography (PET) imaging of neuroblastoma and melanoma with 64Cu-SarAr immunoconjugates. Proc Natl Acad Sci U S A. 2007 Oct 30; 104(44):17489-93. View abstract
  77. Mucoepidermoid carcinoma of bronchus in a pediatric patient: (18)F-FDG PET findings. Pediatr Radiol. 2007 Dec; 37(12):1278-82. View abstract
  78. 3D multidetector CT angiographic evaluation of extralobar pulmonary sequestration with anomalous venous drainage into the left internal mammary vein in a paediatric patient. Br J Radiol. 2006 Sep; 79(945):e99-102. View abstract
  79. The ischiopubic synchondrosis: changing appearance on PET/CT as a mimic of disease. Clin Nucl Med. 2006 Jul; 31(7):414-7. View abstract
  80. On the strong field dependence and nonlinear response to gadolinium contrast agent of proton transverse relaxation rates in dairy cream. Magn Reson Imaging. 2005 Jul; 23(6):757-64. View abstract
  81. Thymoma in a child: case report and review of the literature. Pediatr Surg Int. 2005 Jul; 21(7):548-51. View abstract
  82. Omega-3 fatty acid supplementation prevents hepatic steatosis in a murine model of nonalcoholic fatty liver disease. Pediatr Res. 2005 Mar; 57(3):445-52. View abstract
  83. Right ventricular pseudoaneurysm after modified Norwood procedure. Ann Thorac Surg. 2004 Oct; 78(4):e72-3. View abstract
  84. An integrated vector system for cellular studies of phage display-derived peptides. Anal Biochem. 2002 Sep 15; 308(2):364-72. View abstract
  85. Solitary osteosclerotic plasmacytoma: association with demyelinating polyneuropathy and amyloid deposition. Skeletal Radiol. 2001 Sep; 30(9):527-9. View abstract
  86. Chronic inflammatory pseudotumor arising in the hepatobiliary-pancreatic system: progressive multisystemic organ involvement in four patients. AJR Am J Roentgenol. 1999 Oct; 173(4):1049-54. View abstract
  87. Gene therapy: a primer for radiologists. Radiographics. 1998 Nov-Dec; 18(6):1343-72. View abstract
  88. Cloning of BY55, a novel Ig superfamily member expressed on NK cells, CTL, and intestinal intraepithelial lymphocytes. J Immunol. 1998 Sep 15; 161(6):2780-90. View abstract
  89. Participation of the CD94 receptor complex in costimulation of human natural killer cells. J Immunol. 1998 Feb 15; 160(4):1618-26. View abstract
  90. CD94 ligation induces apoptosis in a subset of IL-2-stimulated NK cells. J Immunol. 1997 Sep 01; 159(5):2154-60. View abstract
  91. Costimulation of human natural killer cell proliferation: role of accessory cytokines and cell contact-dependent signals. Nat Immun. 1996-1997; 15(5):213-26. View abstract
  92. Distinction between gamma c detection and function in YT lymphoid cells and in the granulocyte-macrophage colony-stimulating factor-responsive human myeloid cell line, Tf-1. Blood. 1995 Dec 15; 86(12):4568-78. View abstract
  93. X-linked severe combined immunodeficiency disease and the gamma c receptor component: prospects for molecular diagnosis. Clin Diagn Lab Immunol. 1995 Sep; 2(5):518-23. View abstract
  94. Addendum to SCID, interleukin-2, and the interleukin-2 receptor review. Blood. 1994 Jul 15; 84(2):667-8. View abstract
  95. Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: experiments of nature continue to point the way. Blood. 1994 Feb 01; 83(3):626-35. View abstract
  96. Identification of a direct interaction between interleukin 2 and the p64 interleukin 2 receptor gamma chain. Proc Natl Acad Sci U S A. 1993 Mar 15; 90(6):2428-32. View abstract
  97. Human peripheral gamma delta T cells recognize hsp60 molecules on Daudi Burkitt's lymphoma cells. J Immunol. 1993 Mar 01; 150(5):2046-55. View abstract
  98. Characterization of the interleukin 2 receptors (IL-2R) expressed on human natural killer cells activated in vivo by IL-2: association of the p64 IL-2R gamma chain with the IL-2R beta chain in functional intermediate-affinity IL-2R. J Exp Med. 1992 Aug 01; 176(2):531-41. View abstract
  99. Serum CD25 levels during interleukin-2 therapy: dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother (1991). 1992 Feb; 11(2):111-8. View abstract
  100. Clinical and biologic effects of combination therapy with gamma-interferon and tumor necrosis factor. Cancer. 1992 Jan 15; 69(2):562-71. View abstract
  101. Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding. J Exp Med. 1990 Oct 01; 172(4):1101-14. View abstract
  102. Natural killer cells activated by interleukin 2 treatment in vivo respond to interleukin 2 primarily through the p75 receptor and maintain the p55 (TAC) negative phenotype. Cancer Res. 1990 May 01; 50(9):2683-91. View abstract
  103. Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother. 1989; 29(4):261-9. View abstract
  104. The clinical immunobiology of interleukin-2: potential modified uses for improved cancer treatment. Bull N Y Acad Med. 1989 Jan; 65(1):93-110. View abstract